Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Complications

Prevention and treatment of acute GvHD

Bone Marrow Transplantation volume 41, pages S65–S70 (2008)Cite this article

Abstract

GvHD remains a source of significant morbidity and mortality in the setting of allogeneic haematopoietic SCT. Improving outcomes in stem cell transplant recipients requires additional therapeutic modalities for GvHD, especially for patients who fail to respond to initial therapy with steroids. Moreover, while the absence of acute GvHD (aGvHD) is associated with a higher risk of relapse of the underlying malignant disease, severe aGvHD usually induces the occurrence of life-threatening complications such as severe infections. This article summarizes the current state of aGvHD prophylaxis and treatment.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Bacigalupo A . Management of acute graft-versus-host-disease. Br J Haematol 2007; 137: 87–98.

    Article  CAS  PubMed  Google Scholar 

  2. Blaise D, Kuentz M, Container C . Randomized trail of bone marrow versus lenograstim primed blood cell allogeneic transplantation. J Clin Oncol 2000; 18: 537–546.

    Article  CAS  PubMed  Google Scholar 

  3. Couban S, Simpson R, Barnett MJ, Bredeson C . A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002; 104: 649–654.

    Google Scholar 

  4. Schmitz N, Beksac M, Hasenclever D, Bacigalupo A, Ruutu T, Nagler A et al. Transplantation of mobilized peripheral blood cells to HLA identical siblings with standard risk leukaemia. Blood 2002; 100: 761–767.

    Article  CAS  PubMed  Google Scholar 

  5. Rocha V, Wagner JE, Sobocinski KA, Klein JP, Zhang MJ, Horowitz MM et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. N Eng J Med 2000; 342: 1846–1854.

    Article  CAS  Google Scholar 

  6. Rocha V, Cornish J, Sievers EL, Filipovich A, Locatelli F, Peters C et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001; 97: 2962–2971.

    Article  CAS  PubMed  Google Scholar 

  7. Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA, Wagner JE et al. Haematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Eng J Med 2001; 334: 1860–1861.

    Google Scholar 

  8. Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, van Bekkum DW et al. T-cell depletion of HLA-identical transplants in leukaemia. Blood 1991; 78: 2120–2130.

    CAS  PubMed  Google Scholar 

  9. Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Eng J Med 1998; 339: 1186–1193.

    Article  CAS  Google Scholar 

  10. Hows J, Bradley BA, Gore S, Downie T, Howard M, Gluckman E . Prospective evaluation of unrelated donor bone marrow transplantation. Bone Marrow Transplant 1993; 12: 371–380.

    CAS  PubMed  Google Scholar 

  11. Finke J, Bertz H, Schmoor C, Veelken H, Behringer D, Wäsch R et al. Allogeneic bone marrow transplantation from unrelated donors using in vivo anti-T-cell globulin. Br J Haematol 2000; 111: 303–313.

    Article  CAS  PubMed  Google Scholar 

  12. Byrne JL, Stainer C, Cull G, Haynes AP, Bessell EM, Hale G et al. The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia. Bone Marrow Transplant 2000; 25: 411–417.

    Article  CAS  PubMed  Google Scholar 

  13. Bacigalupo A . Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects. Bone Marrow Transplant 2005; 35: 225–231.

    Article  CAS  PubMed  Google Scholar 

  14. Bacigalupo A, Lamparelli T, Barisione G, Bruzzi P, Guidi S, Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host-disease, chronic lung dysfunction, and late transplant-related mortality: long term follow up of a randomised trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006; 12: 560–565.

    Article  PubMed  Google Scholar 

  15. Trenado A, Sudres M, Tang Q, Maury S, Charlotte F, Grégoire S et al. Ex vivo-expanded CD4 CD25 immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation differentiation of pathogenic T cells. J Immunol 2006; 176: 1266–1273.

    Article  CAS  PubMed  Google Scholar 

  16. Storb R, Leisenring W, Anasetti C, Appelbaum FR, Buckner CD, Bensinger WI et al. Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia. Blood 1994; 83: 2749–2750.

    CAS  PubMed  Google Scholar 

  17. Storb R, Pepe M, Deeg HJ, Anasetti C, Appelbaum FR, Bensinger W et al. Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. Blood 1992; 80: 560–561.

    CAS  PubMed  Google Scholar 

  18. Storb R, Pepe M, Anasetti C, Appelbaum FR, Beatty P, Doney K et al. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? Blood 1990; 76: 1037–1045.

    CAS  PubMed  Google Scholar 

  19. Bacigalupo A, van Lint MT, Occhini D, Gualandi F, Lamparelli T, Sogno G et al. Increased risk of leukaemia with high dose cyclosporine A after allogeneic marrow transplantation. Blood 1991; 77: 1423–1428.

    CAS  PubMed  Google Scholar 

  20. Locatelli F, Zecca M, Rondelli R, Bonetti F, Dini G, Prete A et al. Graft versus host disease prophylaxis with low dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA identical sibling bone marrow transplantation: results of a randomized trial. Blood 2000; 95: 1572–1579.

    CAS  PubMed  Google Scholar 

  21. Lanino E, on behalf of the AIEOP–BMT Group Pretransplant CYA. Preliminary results of a randomized study in pediatric recipients of unrelated-donor BMT. Blood 1999; 94 (Suppl 1): 392.

    Google Scholar 

  22. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062–2068.

    CAS  PubMed  Google Scholar 

  23. Yanik G, Levine JE, Ratanatharathorn V, Dunn R, Ferrara J, Hutchinson RJ . Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantation. Bone Marrow Transplant 2000; 26: 161–167.

    Article  CAS  PubMed  Google Scholar 

  24. Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004; 34: 621–625.

    Article  CAS  PubMed  Google Scholar 

  25. Klyshnenkova EN, Mosca J, McIntosh KR . Human mesenchymal stem cells suppress allogeneic T cell responses in vitro: implications for allogeneic transplantation. Blood 1998; 92: 642a.

    Google Scholar 

  26. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30: 42–48.

    Article  PubMed  Google Scholar 

  27. Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK et al. Co-transplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005; 11: 389–398.

    Article  PubMed  Google Scholar 

  28. Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE et al. Donor-derived mesenchymal stem cells are immunogeneic in an allogeneic host and stimulate donor graft rejection in a non-myeloablative setting. Blood 2006; 15: 108 2114–2120.

    Google Scholar 

  29. Alcindor T, Gorgun G, Miller KB, Roberts TF, Sprague K, Schenkein DP et al. Immunologic mechanism of extracorporeal photochemotherapy (ECP) in chronic GVHD. Blood 2001; 98: 650a (abstract 2729).

    Article  Google Scholar 

  30. Peritt D . Potential mechanism of photopheresis in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 7–12.

    Article  CAS  PubMed  Google Scholar 

  31. Chan G, Foss FM, Roberts T, Sprague K, Schenkein D, Miller KB . Decreased acute and chronic graft versus host disease with early full donor engraftment following a pentostatin-based preparative regimen for allogeneic bone marrow transplant in high-risk patients. Blood 2001; 98: 383a (abstract 1612).

    Article  Google Scholar 

  32. Ruggeri L, Shlomchik WD . Donor-vs-recipient alloreactive NK cells prevent GVHD by killing host APC in MHC disparate hematopoietic transplants. Blood 2001; 98: 813a (abstract 3378).

    Article  Google Scholar 

  33. Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F et al. Treatment of high-risk acute leukaemia with T-cell-depleted stem cell from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339: 1186–1193.

    Article  CAS  PubMed  Google Scholar 

  34. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Non-myeloablative stem cell transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–763.

    CAS  PubMed  Google Scholar 

  35. Kottardis PD, Chakraverty, Milligan DW, Chakrabarti S, Robinson S, Chopra R et al. A non-myeloablative regimen for allogeneic stem cell transplantation with a low incidence of GVHD. Bone Marrow Transplant 2000; 25: S26.

    Article  Google Scholar 

  36. Lowsky R, Takahashi T, Liu YP, Dejbakhsh-Jones S, Grumet FC, Shizuru JA et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med 2005; 353: 1321–1331.

    Article  CAS  PubMed  Google Scholar 

  37. Blaise D, Olive D, Michallet M, Marit G, Leblond V, Maraninchi D . Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis. Lancet 1995; 345: 1144–1146.

    Article  CAS  PubMed  Google Scholar 

  38. Anasetti C, Lin A, Nademanee A, Gluckman E, Messner H, Beatty P et al. A phase II/III randomized double blind, placebo-controlled multicentre trial of humanised anti-Tac for prevention of acute graft-versus-host disease in recipients of marrow transplant from unrelated donors. Blood 1995; 86 (Suppl 1): 621a.

    Google Scholar 

  39. Holler E, Kolb HJ, Mittermüller J, Kaul M, Ledderose G, Duell T et al. Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor α (TNF α) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF α (MAK 195F). Blood 1995; 86: 890–899.

    CAS  PubMed  Google Scholar 

  40. Blazar BR . Response of 443 patients to steroids as primary therapy for acute GvHD: comparison of grading system. Biol Blood Marrow Transplant 2002; 47: 387–394.

    Google Scholar 

  41. Van Lint MT, Uderzo C, Locasciulli A, Majolino I, Scimé R, Locatelli F et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6 methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood 1998; 92: 2288–2293.

    CAS  PubMed  Google Scholar 

  42. Cragg L, Blazar BR, Defor T, Kolatker N, Miller W, Kersey J et al. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant 2000; 6: 441–447.

    Article  CAS  PubMed  Google Scholar 

  43. Van Lint MT, Milone G, Leotta S, Uderzo C, Scimè R, Dallorso S . Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood 2006; 107: 4177–4181.

    Article  CAS  PubMed  Google Scholar 

  44. Antin JH, Chen AR, Couriel DR, Ho VT, Nash RA, Weisdorf D . Novel approaches to the therapy of steroid resistant acute graft versus host disease. Biol Blood Marrow Transplant 2004; 10: 655–668.

    Article  CAS  PubMed  Google Scholar 

  45. Antin JH . Approaches to graft-vs-host disease. Paediatr Transplant 2005; 9: 71–75.

    Article  CAS  Google Scholar 

  46. Furlong T, Storb R, Anasetti C, Appelbaum FR, Deeg HJ, Doney K et al. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. Bone Marrow Transplant 2000; 26: 985–991.

    Article  CAS  PubMed  Google Scholar 

  47. Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt S, Khouri I et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000; 95: 83–89.

    CAS  PubMed  Google Scholar 

  48. Marty FM, Lee SJ, Fahey MM, Alyea EP, Soiffer RJ, Antin JH et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors on non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients. A cohort study. Blood 2003; 102: 2768–2776.

    Article  CAS  PubMed  Google Scholar 

  49. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C et al. Tumor necrosis factor alpha blockade for the treatment of acute GVHD. Blood 2004; 104: 649–654.

    Article  CAS  PubMed  Google Scholar 

  50. Deeg HJ, Blazar BR, Bolwell BJ, Long GD, Schuening F, Cunningham J et al. Treatment of steroid-refractory acute graft-verus-host-disease with anti-CD147 monoclonal antibody ABX-CBL. Blood 2001; 98: 2052–2058.

    Article  CAS  PubMed  Google Scholar 

  51. Carpenter PA, Appelbaum FR, Corey L, Deeg HJ, Doney K, Gooley T et al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 2002; 99: 2712–2719.

    Article  CAS  PubMed  Google Scholar 

  52. Jacobsohn DA, Vogelsang GB . Novel pharmacotherapeutic approaches to prevention and treatment of GvHD. Drugs 2001; 62: 879–889.

    Article  Google Scholar 

  53. Benito AI, Furlong T, Martin PJ, Anasetti C, Appelbaum FR, Doney K et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 2001; 72: 1924–1929.

    Article  CAS  PubMed  Google Scholar 

  54. Bolaños-Meade J, Jacobsohn DA, Margolis J, Ogden A, Wientjes MG, Byrd JC et al. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol 2005; 20: 2661–2668.

    Article  Google Scholar 

  55. Ringdén O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lönnies H et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81: 1390–1397.

    Article  PubMed  Google Scholar 

  56. Greinix HT, Knobler RM, Worel N, Schneider B, Schneeberger A, Hoecker P et al. Intensified extracorporeal photochemotherapy in severe acute graft-versus-host disease results in long-term improved survival. Haematologica 2006; 3: 555–580.

    Google Scholar 

  57. Greinix HT, Socié G, Bacigalupo A, Holler E, Edinger MG, Apperley JF et al. Assessing the potential role of photopheresis in hematopoietic stem cell transplant. Bone Marrow Transplant 2006; 38: 265–273.

    Article  CAS  PubMed  Google Scholar 

  58. Messina C, Locatelli F, Lanino E, Uderzo C, Zacchello G, Cesaro S et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol 2003; 122: 118–127.

    Article  CAS  PubMed  Google Scholar 

  59. Komanduri KV, Couriel D, Champlin RE . disease after allogeneic stem cell transplantation: evolving concepts and novel therapies including photopheresis. Biol Blood Marrow Transplant 2006; 12: 1–6; review.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bone Marrow Unit, Paediatric Onco-,

    C Messina, M P Calò & E Calore

  2. Haematology Clinic,

    C Messina, M P Calò & E Calore

  3. , University of Padova, Padova, Italy

    C Messina, M P Calò & E Calore

  4. Department of Haematology-Oncology, Bone Marrow Unit, G Gaslini Children's Research Institute, Genova, Italy

    M Faraci, V de Fazio & G Dini

Authors
  1. C Messina
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Faraci
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V de Fazio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G Dini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M P Calò
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E Calore
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the EBMT Paediatric Working Party

Corresponding author

Correspondence to C Messina.

Additional information

Conflict of interest

None of the authors declared any financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Messina, C., Faraci, M., de Fazio, V. et al. Prevention and treatment of acute GvHD. Bone Marrow Transplant 41 (Suppl 2), S65–S70 (2008). https://doi.org/10.1038/bmt.2008.57

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.57

Keywords

This article is cited by

Search

Advanced search

Quick links